Online inquiry

IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1211MR)

This product GTTS-WQ1211MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TPBG gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Non-small lung carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001166392.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7162
UniProt ID Q13641
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1211MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11910MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ11823MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ1931MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ8721MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ621MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ1852MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ2330MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ7175MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW